COTELLIC (cobimetinib), anti-MEK, protein kinase inhibitor
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
May 25 2016
Reason for request
Inclusion
Moderate improvement in the first-line treatment of unresectable or metastatic melanoma, in patients with a BRAF V600 mutation
- COTELLIC now has Marketing Authorisation in combination with vemurafenib, in the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Its combination with vemurafenib (ZELBORAF) improves progression-free survival (+3.7 months) and overall survival (+4.9 months) in comparison with vemurafenib alone.
- Like the trametinib/dabrafenib (MEKINIST/TAFINLAR) combination, the cobimetinib/vemurafenib combination is a first-line treatment in this indication.
Clinical Benefit
Substantial |
- |
Clinical Added Value
moderate |
- |
Therapeutic use
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments